Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Bemiparin sodium: Difference between pages
Appearance
(Difference between pages)
Content deleted Content added
Saving copy of the {{drugbox}} taken from revid 461583394 of page Bemiparin_sodium for the Chem/Drugbox validation project (updated: 'CAS_number'). |
Citation bot (talk | contribs) Removed parameters. | Use this bot. Report bugs. | Suggested by AManWithNoPlan | #UCB_CommandLine |
||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid [{{fullurl:Bemiparin_sodium|oldid=461583394}} 461583394] of page [[Bemiparin_sodium]] with values updated to verified values.}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
||
| Watchedfields = changed |
| Watchedfields = changed |
||
| verifiedrevid = |
| verifiedrevid = 461744899 |
||
| IUPAC_name = |
| IUPAC_name = |
||
| image = |
| image = File:Heparin General Structure V.1.svg |
||
⚫ | |||
| tradename = Badyket, Ivor, Hibor, Zibor, others |
|||
⚫ | |||
| tradename = |
|||
| Drugs.com = {{drugs.com|international|bemiparin-sodium}} |
| Drugs.com = {{drugs.com|international|bemiparin-sodium}} |
||
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
||
| pregnancy_US = <!-- A / B / C / D / X --> |
| pregnancy_US = <!-- A / B / C / D / X --> |
||
| pregnancy_category = |
| pregnancy_category = |
||
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
||
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = [[Subcutaneous injection]] (except for [[haemodialysis]]) |
||
⚫ | |||
⚫ | |||
⚫ | |||
| protein_bound = |
|||
⚫ | |||
| |
| metabolism = |
||
⚫ | |||
| metabolism = |
|||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
| ATC_prefix = B01 |
| ATC_prefix = B01 |
||
| ATC_suffix = AB12 |
| ATC_suffix = AB12 |
||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite| |
| DrugBank_Ref = {{drugbankcite|changed|drugbank}} |
||
| DrugBank = |
| DrugBank = DB09258 |
||
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
||
| ChemSpiderID = |
| ChemSpiderID = none |
||
⚫ | |||
⚫ | |||
⚫ | |||
| molecular_weight = 3600 |
|||
⚫ | |||
| |
| molecular_weight_comment = g/mol (average) |
||
}} |
}} |
||
'''Bemiparin''' (trade names '''Ivor''' and '''Zibor''', among others) is an [[antithrombotic]] and belongs to the group of [[low molecular weight heparin]]s (LMWH).<ref>{{cite journal | vauthors = Chapman TM, Goa KL | title = Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis | journal = Drugs | volume = 63 | issue = 21 | pages = 2357–77 | year = 2003 | pmid = 14524738 | doi = 10.2165/00003495-200363210-00009 | s2cid = 195692039 }}</ref> |
|||
==Medical uses== |
|||
Bemiparin is used for the prevention of [[thromboembolism]] after surgery, and to prevent blood clotting in the [[extracorporeal]] circuit in [[haemodialysis]].<ref name="AC">{{cite book|title=Austria-Codex|at=Ivor 2500 IE Anti-Xa/0,2 ml Injektionslösung in Fertigspritzen|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2018|language=de}}</ref> |
|||
==Contraindications== |
|||
The medication is contraindicated in patients with a history of [[heparin-induced thrombocytopenia]] with or without [[disseminated intravascular coagulation]]; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or [[pancreas]] impairment; and acute or [[subacute bacterial endocarditis]].<ref name="AC" /> |
|||
== Interactions == |
|||
No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, [[aspirin]] and other [[NSAID]]s, [[antiplatelet drug]]s, and [[corticosteroid]]s.<ref name="AC" /> |
|||
==Chemistry== |
|||
Like [[semuloparin]], bemiparin is classified as an ultra-LMWH because of its low [[molecular mass]] of 3600 g/mol on average.<ref>{{cite journal | vauthors = Planès A | title = Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism | journal = Expert Opinion on Pharmacotherapy | volume = 4 | issue = 9 | pages = 1551–61 | date = September 2003 | pmid = 12943485 | doi = 10.1517/14656566.4.9.1551 | s2cid = 13566575 }}</ref> ([[Enoxaparin]] has 4500 g/mol.) These heparins have lower anti-[[thrombin]] activity than classical LMWHs and act mainly on [[factor Xa]], reducing the risk of bleeding.<ref>{{cite journal | vauthors = Jeske WP, Hoppensteadt D, Gray A, Walenga JM, Cunanan J, Myers L, Fareed J, Bayol A, Rigal H, Viskov C | title = A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparin | journal = Thrombosis Research | volume = 128 | issue = 4 | pages = 361–7 | date = October 2011 | pmid = 21458847 | doi = 10.1016/j.thromres.2011.03.001 }}</ref> |
|||
== References == |
|||
{{reflist}} |
|||
== External links == |
|||
* {{MeshName|bemiparin}} |
|||
{{Antithrombotics}} |
|||
[[Category:Heparins]] |
|||
[[Category:Organic sodium salts]] |